Ying Huang, Legend Biotech CEO
February 28, 2022 05:48 PM ESTUpdated March 1, 07:06 AM
Pharma
FDA+

'We are ready to go': FDA OKs J&J and Leg­end's BC­MA CAR-T, set­ting stage for show­down with Bris­tol My­ers

Nicole DeFeudis

Editor

Move over, Bris­tol My­ers Squibb. Af­ter de­lay­ing their de­ci­sion by three months to re­view new in­for­ma­tion, the FDA has cleared John­son & John­son and Leg­end …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

The End­points 2024 win­ners and losers list: Who was up and who was down in bio­phar­ma

Up­dat­ed: No­vo’s 23% weight loss with Ca­griSe­ma falls short of high ex­pec­ta­tions, new tri­al planned

FDA ap­proves Hu­ma­cyte’s lab-grown blood ves­sels in mile­stone for re­gen­er­a­tive med­i­cine

Ac­cel­er­at­ed ap­proval brings Pfiz­er's BRAF in­hibitor to first-line pa­tients

Ex­clu­sive: Flori­da can­cer biotech rais­es $100M Se­ries A

Sofinno­va out­lines $550M fund af­ter IPOs and M&A deals

A service from the Financial Times